Evaluation of synthetic single domain antibodies against the HPV16 E6 protein and their potential for commercialization

Almost all cervical cancers are caused by a Human papillomavirus (HPV) infection. The current standard of care relies primarily on chemo- or radiation-therapy and surgery. These methods have several side effects leading to high morbidity of the affected patients. There is an urgent need to develop new therapeutic approaches that are more efficient, efficacious, and produce fewer side effects. To achieve these objectives, Dr. Zehbe’s lab is developing therapeutic strategies with a focus on targeting the HPV E6 protein, the main culprit in HPV carcinogenesis. It is anticipated that such molecules will induce the death of the HPV-containing/cancerous cells while causing limited to no side effects. Our lab has produced synthetic single domain antibodies (sdAbs), which enter tissues rapidly to target sites unaccessible to “traditional” 10 times larger antibodies making them ideal to treat infected cells efficiently. Apart from their therapeutic potential, synthetic sdAbs are also useful biotechnology tools for diagnostic purposes. The objective of the proposed project is to evaluate approximately 10 anti-E6 synthetic sdAbs in different applications to test their therapeutic and diagnostic potential. They will then be patented in partnership with the Thunder Bay Regional Health Research Institute (TBRHRI).

Faculty Supervisor:

Ingeborg Zehbe

Student:

Partner:

Thunder Bay Regional Health Research Institute

Discipline:

Life Sciences

Sector:

Health and Related Sciences & Technology; Professional, scientific and technical services

University:

Lakehead University

Program: